結合または屈曲: NMRベースの形状測定法によって,アロステリックAblキナーゼアゴニストとアンタゴニストの区別
Wolfgang Jahnke1, Robert M Grotzfeld, Xavier Pellé
1Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. wolfgang.jahnke@novartis.com
Journal of the American Chemical Society
|May 11, 2010
まとめ
ミリスタートポケットを標的とした新しいBcr-Abl阻害剤が特定されました. 機能的活動は,ヘリックス_Iの特定の形状の変化を誘導し,慢性骨髄性白血病 (CML) 治療における抗体と抗体とを区別することに依存しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 薬理学 薬理学とは
背景:
- Bcr-Ablを標的とするアロステリック阻害剤は,慢性骨髄性白血病 (CML) の有望な治療戦略です.
- フラグメントベースのスクリーニングは,ミリスタートポケットに結合する新しいAbl阻害剤を発見するために使用されました.
研究 の 目的:
- ミリスタートポケットリガンドの機能的活性を調べるために.
- Bcr-Abl阻害剤の有効性の構造的決定因子を特定するために.
- Ablコンファメーション状態をモニタリングするためのアッセイを開発する.
主な方法:
- Abl阻害剤の断片ベースのスクリーニング.
- C端末ヘリックス_I.I.をモニタリングするためのNMRベースの構成測定法.
- c-Ablの活性化を確認するための生化学的測定法.
主要な成果:
- すべてのミリスタートポケットリガンドが機能的なBcr-Abl阻害剤であるとは限らない.
- C端末ヘリックス_Iの形状状態は,機能活動の重要な決定因子です.
- ヘリックス_I 曲解を誘導するリガンドは機能的アンタゴニストであり,この変化を誘導しないリガンドはキナーゼアゴニストである.
- c-Ablのアロステリックアゴニスト活性化が生化学的に確認されました.
結論:
- helix_Iの形状状態は,ミリスタートポケットリガンド結合の機能的結果を決定する.
- この形状測定法では,機能的アンタゴニストとアゴニストを区別するための方法を提供します.
- これらのメカニズムの理解は,より効果的なCML治療法の開発を導くことができます.
関連する概念動画
Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...


